Oscar G. Bukstein
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Oscar G. Bukstein has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
Jack Cornelius
3 shared publicationsA C Trunzo
1 shared publicationA. Thomas McLellan
1 shared publicationAnna Pond
1 shared publicationAnnette C. Trunzo
1 shared publicationCecilia A. Essau
1 shared publication
Latest Publications
- 1 February 2011
- Published by SAGE Publications in Journal of Child and Adolescent Psychopharmacology
- Vol. 21 (1) , 57-66
Medication Refusal in Children with Oppositional Defiant Disorder or Conduct Disorder and Comorbid Attention-Deficit/Hyperactivity Disorder: Medication History and Clinical Correlates
Objective: This study examines the characteristics of 96 children with attention-deficit/hyperactivity disorder (ADHD) and their families who refused a recommendation for medication as part of their treatment for disruptive disorders. Methods: The ADHD cases were taken from a sample of 139 youth (age 6–11) who were recruited for a clinical trial that compared the administration of a modular psychosocial treatment in an outpatient clinic or community settings. Medication management was an optional treatment module for children with ADHD in both conditions. Children who were (vs. were not) taking medication at intake, and children who accepted (vs. refused) medication recommendations during the study were compared on diagnostic and clinical measures related to child, school, parent, and family domains of functioning. Results: Parents of 30% of the children refused study medication for ADHD. Parental medication acceptability and intake correlated highly with both medication history and study refusal of medication. Increased parental self-efficacy and emotional support for their youth correlated with medication refusal. No demographics and few child or school factors were associated with medication refusal. Medication use was associated with reductions in some key ADHD symptoms, but did not affect disruptive behaviors as did the psychosocial interventions. Conclusion: Medication refusers remain poorly understood but certain correlates, such as parental self-efficacy, parental emotional support for their youth, and medication acceptability, warrant further evaluation.
- 1 February 2011
- Published by SAGE Publications in Journal of Child and Adolescent Psychopharmacology
- Vol. 21 (1) , 57-66
Medication Refusal in Children with Oppositional Defiant Disorder or Conduct Disorder and Comorbid Attention-Deficit/Hyperactivity Disorder: Medication History and Clinical Correlates
Objective: This study examines the characteristics of 96 children with attention-deficit/hyperactivity disorder (ADHD) and their families who refused a recommendation for medication as part of their treatment for disruptive disorders. Methods: The ADHD cases were taken from a sample of 139 youth (age 6–11) who were recruited for a clinical trial that compared the administration of a modular psychosocial treatment in an outpatient clinic or community settings. Medication management was an optional treatment module for children with ADHD in both conditions. Children who were (vs. were not) taking medication at intake, and children who accepted (vs. refused) medication recommendations during the study were compared on diagnostic and clinical measures related to child, school, parent, and family domains of functioning. Results: Parents of 30% of the children refused study medication for ADHD. Parental medication acceptability and intake correlated highly with both medication history and study refusal of medication. Increased parental self-efficacy and emotional support for their youth correlated with medication refusal. No demographics and few child or school factors were associated with medication refusal. Medication use was associated with reductions in some key ADHD symptoms, but did not affect disruptive behaviors as did the psychosocial interventions. Conclusion: Medication refusers remain poorly understood but certain correlates, such as parental self-efficacy, parental emotional support for their youth, and medication acceptability, warrant further evaluation.
- 1 September 2010
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 122 (5) , 69-77
Clinical Practice Guidelines for Attention-Deficit/Hyperactivity Disorder: A Review
The prevalence and public health importance of attention-deficit/hyperactivity disorder (ADHD) as well as its impact on public health has led various groups to develop clinical practice guidelines (CPGs). Clinical practice guidelines are systematically developed statements designed to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances. In this article, we review 9 CPGs, including their development process, the recommendation of specific clinical actions, and advocacy of recommendations based on limited evidence. Despite the differences between these CPGs for ADHD, they appear to be complementary and not inconsistent. The CPGs all recommend: a structured approach to diagnosis and treatment; attention to psychiatric comorbidity and other ADHD-related conflicts during an individual's lifespan; consideration of medication (usually stimulants) and psychosocial therapies; and follow-up and monitoring of patient response. A patient-centered approach is also recommended in the evaluation and treatment of ADHD, although it is less evidence based than recommended therapies.
- 1 September 2010
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 122 (5) , 69-77
Clinical Practice Guidelines for Attention-Deficit/Hyperactivity Disorder: A Review
The prevalence and public health importance of attention-deficit/hyperactivity disorder (ADHD) as well as its impact on public health has led various groups to develop clinical practice guidelines (CPGs). Clinical practice guidelines are systematically developed statements designed to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances. In this article, we review 9 CPGs, including their development process, the recommendation of specific clinical actions, and advocacy of recommendations based on limited evidence. Despite the differences between these CPGs for ADHD, they appear to be complementary and not inconsistent. The CPGs all recommend: a structured approach to diagnosis and treatment; attention to psychiatric comorbidity and other ADHD-related conflicts during an individual's lifespan; consideration of medication (usually stimulants) and psychosocial therapies; and follow-up and monitoring of patient response. A patient-centered approach is also recommended in the evaluation and treatment of ADHD, although it is less evidence based than recommended therapies.
- 1 July 2010
- Published by Elsevier in Child and Adolescent Psychiatric Clinics of North America
- Vol. 19 (3) , 609-623
Management of the Adolescent with Substance Use Disorders and Comorbid Psychopathology
- 1 July 2010
- Published by Elsevier in Child and Adolescent Psychiatric Clinics of North America
- Vol. 19 (3) , 609-623
Management of the Adolescent with Substance Use Disorders and Comorbid Psychopathology
- Open Access
- 10 December 2009
- Published by Springer Nature in Child and Adolescent Psychiatry and Mental Health
- Vol. 3 (1) , 39
Does switching from oral extended-release methylphenidate to the methylphenidate transdermal system affect health-related quality-of-life and medication satisfaction for children with attention-deficit/hyperactivity disorder?
To evaluate health-related quality of life (HRQL) and medication satisfaction after switching from a stable dose of oral extended-release methylphenidate (ER-MPH) to methylphenidate transdermal system (MTS) via a dose-transition schedule in children with attention-deficit/hyperactivity disorder (ADHD). In a 4-week, multisite, open-label study, 171 children (164 in the intent-to-treat [ITT] population) aged 6-12 years diagnosed with ADHD abruptly switched from a stable dose of oral ER-MPH to MTS nominal dosages of 10, 15, 20, and 30 mg using a predefined dose-transition schedule. Subjects remained on the scheduled dose for the first week, after which the dose was then titrated to an optimal effect. The ADHD Impact Module-Children (AIM-C), a disease-specific validated HRQL survey instrument measuring child and family impact, was used to assess the impact of ADHD symptoms on the lives of children and their families at baseline and study endpoint. Satisfaction with MTS use was assessed via a Medication Satisfaction Survey (MSS) at study endpoint. Both the AIM-C and MSS were completed by a caregiver (parent/legally authorized representative). Tolerability was monitored by spontaneous adverse event (AE) reporting. AIM-C child and family HRQL mean scores were above the median possible score at baseline and were further improved at endpoint across all MTS doses. Similar improvements were noted for behavior, missed doses, worry, and economic impact AIM-C item scores. Overall, 93.8% of caregivers indicated a high level of satisfaction with their child's use of the study medication. The majority of treatment-emergent AEs (> 98%) were mild to moderate in intensity, and the most commonly reported AEs included headache, decreased appetite, insomnia, and abdominal pain. Seven subjects discontinued the study due to intolerable AEs (n = 3) and application site reactions (n = 4). This study demonstrates that MTS, when carefully titrated to optimal dose, may further improve child and family HRQL, as well as behavioral, medication worry, and economic impact item scores, as measured by the AIM-C in subjects switching to MTS from a stable dose of routinely prescribed oral ER-MPH after a short treatment period. Furthermore, following the abrupt conversion from oral ER-MPH to MTS, the majority of caregivers reported being highly satisfied with MTS as a treatment option for their children with ADHD. NCT00151983
- 10 December 2009
- Published by Springer Nature in Child and Adolescent Psychiatry and Mental Health
- Vol. 3 (1) , 39
Open AccessDoes switching from oral extended-release methylphenidate to the methylphenidate transdermal system affect health-related quality-of-life and medication satisfaction for children with attention-deficit/hyperactivity disorder?
To evaluate health-related quality of life (HRQL) and medication satisfaction after switching from a stable dose of oral extended-release methylphenidate (ER-MPH) to methylphenidate transdermal system (MTS) via a dose-transition schedule in children with attention-deficit/hyperactivity disorder (ADHD). In a 4-week, multisite, open-label study, 171 children (164 in the intent-to-treat [ITT] population) aged 6-12 years diagnosed with ADHD abruptly switched from a stable dose of oral ER-MPH to MTS nominal dosages of 10, 15, 20, and 30 mg using a predefined dose-transition schedule. Subjects remained on the scheduled dose for the first week, after which the dose was then titrated to an optimal effect. The ADHD Impact Module-Children (AIM-C), a disease-specific validated HRQL survey instrument measuring child and family impact, was used to assess the impact of ADHD symptoms on the lives of children and their families at baseline and study endpoint. Satisfaction with MTS use was assessed via a Medication Satisfaction Survey (MSS) at study endpoint. Both the AIM-C and MSS were completed by a caregiver (parent/legally authorized representative). Tolerability was monitored by spontaneous adverse event (AE) reporting. AIM-C child and family HRQL mean scores were above the median possible score at baseline and were further improved at endpoint across all MTS doses. Similar improvements were noted for behavior, missed doses, worry, and economic impact AIM-C item scores. Overall, 93.8% of caregivers indicated a high level of satisfaction with their child's use of the study medication. The majority of treatment-emergent AEs (> 98%) were mild to moderate in intensity, and the most commonly reported AEs included headache, decreased appetite, insomnia, and abdominal pain. Seven subjects discontinued the study due to intolerable AEs (n = 3) and application site reactions (n = 4). This study demonstrates that MTS, when carefully titrated to optimal dose, may further improve child and family HRQL, as well as behavioral, medication worry, and economic impact item scores, as measured by the AIM-C in subjects switching to MTS from a stable dose of routinely prescribed oral ER-MPH after a short treatment period. Furthermore, following the abrupt conversion from oral ER-MPH to MTS, the majority of caregivers reported being highly satisfied with MTS as a treatment option for their children with ADHD. NCT00151983
- 15 May 2009
- Published by Informa Healthcare in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 5 (6) , 661-665
Transdermal methylphenidate system: old wine in a new bottle
Background: The methylphenidate transdermal system (MTS) is a novel formulation of methylphenidate, a psychostimulant, in an adhesive-based matrix transdermal system (patch) that is applied to intact skin. This is deliverable in a transdermal patch for the treatment of attention-deficit/hyperactivity disorders. Objective: This paper seeks to review the supporting data for the use of the MTS patch, including its efficacy, safety and other considerations in its use. Methods: Clinical studies using MTS are reviewed. Results/conclusion: The MTS patch shows similar levels of efficacy and safety as other methylphenidate formulations and stimulants, although the time to onset of effects may be longer. The patch delivery system allows for flexibility in the duration of effect and reduced reliance on oral administration.
- 15 May 2009
- Published by Informa Healthcare in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 5 (6) , 661-665
Transdermal methylphenidate system: old wine in a new bottle
Background: The methylphenidate transdermal system (MTS) is a novel formulation of methylphenidate, a psychostimulant, in an adhesive-based matrix transdermal system (patch) that is applied to intact skin. This is deliverable in a transdermal patch for the treatment of attention-deficit/hyperactivity disorders. Objective: This paper seeks to review the supporting data for the use of the MTS patch, including its efficacy, safety and other considerations in its use. Methods: Clinical studies using MTS are reviewed. Results/conclusion: The MTS patch shows similar levels of efficacy and safety as other methylphenidate formulations and stimulants, although the time to onset of effects may be longer. The patch delivery system allows for flexibility in the duration of effect and reduced reliance on oral administration.
- 27 March 2009
- Published by Springer Nature in Current Attention Disorders Reports
- Vol. 1 (1) , 12-18
Substance use disorders and attention-deficit/hyperactivity disorder: A review of recent developments
- 27 March 2009
- Published by Springer Nature in Current Attention Disorders Reports
- Vol. 1 (1) , 12-18
Substance use disorders and attention-deficit/hyperactivity disorder: A review of recent developments
- 1 August 2008
- Published by American Academy of Pediatrics (AAP)
- Vol. 19 (2) , 242-253
Substance Use Disorders in Adolescents With Attention-Deficit/Hyperactivity Disorder
Attention-deficit/hyperactivity disorder and substance use disorders are commonly observed together, particularly in clinical populations of adolescents. The co-occurrence of these problems is common and presents challenges for the clinician in assessment and management. This article will review the extent of the problem, the relationship in terms of risk and prognosis, and management issues, including the use of stimulant and nonstimulant medications and the risk of abuse, misuse, and diversion.
- 1 August 2008
- Published by American Academy of Pediatrics (AAP)
- Vol. 19 (2) , 242-253
Substance Use Disorders in Adolescents With Attention-Deficit/Hyperactivity Disorder
Attention-deficit/hyperactivity disorder and substance use disorders are commonly observed together, particularly in clinical populations of adolescents. The co-occurrence of these problems is common and presents challenges for the clinician in assessment and management. This article will review the extent of the problem, the relationship in terms of risk and prognosis, and management issues, including the use of stimulant and nonstimulant medications and the risk of abuse, misuse, and diversion.
- 31 January 2008
- Vol. 10 (1) , 24
Substance abuse in patients with attention-deficit/hyperactivity disorder.
Substance use disorder (SUD) is a common comorbidity of attention-deficit/hyperactivity disorder (ADHD) that is frequently seen during adolescence. Physicians who treat patients with ADHD need to be aware of both the behavioral and medical signs of substance abuse and closely screen their patients for SUD. Optimal treatment of the symptoms of ADHD is the most effective way to reduce the incidence of SUD, but the use of stimulants, the first-line therapy for ADHD, is associated with an appreciable degree of abuse and misuse of therapeutic drugs. Cardiovascular and psychiatric risks with ADHD drugs have resulted in recent labeling changes for these drugs. A correct diagnosis of ADHD is important in validating the use of stimulant medication. New strategies for effectively treating ADHD that may minimize the risk for drug abuse are being developed and include extended-release formulations of currently used drugs, new nonstimulant drugs for the treatment of ADHD, and novel prodrugs that optimize therapeutic plasma concentrations of drugs. Nonmedication or psychosocial treatments, especially for adult ADHD, are also available. Further assessment of these strategies should permit the development of new approaches to the treatment of ADHD that reduce the risk for abuse and misuse of stimulant medications.
- 31 January 2008
- Vol. 10 (1) , 24
Substance abuse in patients with attention-deficit/hyperactivity disorder.
Substance use disorder (SUD) is a common comorbidity of attention-deficit/hyperactivity disorder (ADHD) that is frequently seen during adolescence. Physicians who treat patients with ADHD need to be aware of both the behavioral and medical signs of substance abuse and closely screen their patients for SUD. Optimal treatment of the symptoms of ADHD is the most effective way to reduce the incidence of SUD, but the use of stimulants, the first-line therapy for ADHD, is associated with an appreciable degree of abuse and misuse of therapeutic drugs. Cardiovascular and psychiatric risks with ADHD drugs have resulted in recent labeling changes for these drugs. A correct diagnosis of ADHD is important in validating the use of stimulant medication. New strategies for effectively treating ADHD that may minimize the risk for drug abuse are being developed and include extended-release formulations of currently used drugs, new nonstimulant drugs for the treatment of ADHD, and novel prodrugs that optimize therapeutic plasma concentrations of drugs. Nonmedication or psychosocial treatments, especially for adult ADHD, are also available. Further assessment of these strategies should permit the development of new approaches to the treatment of ADHD that reduce the risk for abuse and misuse of stimulant medications.
- 1 April 2006
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 6 (4) , 541-549
Therapeutic challenges of attention-deficit hyperactivity disorder with substance use disorders
Attention-deficit hyperactivity disorder (ADHD), a common neuropsychiatric disorder of childhood, adolescence and adulthood, is frequently comorbid with substance use disorders (SUDs) in both adolescents and adults. This paper will provide an overview of the relationship between ADHD and SUDs and discuss the primary areas of therapeutic challenge in the treatment of individuals with comorbid ADHD and SUDs, including the diagnosis of ADHD in populations with SUDs, selecting appropriate agents for use and prevention of abuse and/or diversion of the therapeutic pharmacological agents used in ADHD treatment. The authors will also provide a discussion on the future of research and treatment in this area and key issues for clinicians.
- 1 April 2006
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 6 (4) , 541-549
Therapeutic challenges of attention-deficit hyperactivity disorder with substance use disorders
Attention-deficit hyperactivity disorder (ADHD), a common neuropsychiatric disorder of childhood, adolescence and adulthood, is frequently comorbid with substance use disorders (SUDs) in both adolescents and adults. This paper will provide an overview of the relationship between ADHD and SUDs and discuss the primary areas of therapeutic challenge in the treatment of individuals with comorbid ADHD and SUDs, including the diagnosis of ADHD in populations with SUDs, selecting appropriate agents for use and prevention of abuse and/or diversion of the therapeutic pharmacological agents used in ADHD treatment. The authors will also provide a discussion on the future of research and treatment in this area and key issues for clinicians.
- 9 March 2006
- Published by Cambridge University Press (CUP)
- p. 241-263
Psychopharmacology of adolescents with substance use disorders: using diagnostic-specific treatments
- 9 March 2006
- Published by Cambridge University Press (CUP)
- p. 241-263
Psychopharmacology of adolescents with substance use disorders: using diagnostic-specific treatments